- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 - - NDA submission and launch preparation on track - - Conference call today at 8:00 a.m. EST -
LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the fourth quarter and year-ended 30 September 2016.
“In 2016 GW has completed three positive Phase 3 trials for Epidiolex in patients with two different rare treatment resistant forms of childhood-onset epilepsy and we are making good progress towards an NDA submission. Our sights are now focused on Epidiolex approval and accelerating our preparations for a highly successful launch,” stated Justin Gover, GW’s Chief Executive Officer. “Our goal is to provide the children and their families suffering from these highly treatment-resistant forms of childhood-onset epilepsy with a much needed new prescription option as quickly as possible.”
2016 OPERATIONAL HIGHLIGHTS
Epidiolex® (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS)
Phase 3 trials:
Positive results in a pivotal Phase 3 Dravet syndrome trial
Positive results in two pivotal Phase 3 LGS trials
Positive data presented at the American Epilepsy Society Annual Meeting
Regulatory:
Positive Dravet syndrome pre-NDA meeting held with FDA in July 2016
Positive CMC pre-NDA meeting held with FDA in November 2016
NDA submission for both Dravet and LGS indications expected at end of H1 2017, just 3 years since opening of IND
Preparations advancing for EU regulatory submission in H2 2017
Manufacturing scale-up:
Manufacturing scale-up on track to deliver significant commercial launch inventory
Expanded access program and open label extension:
98% of patients who complete Phase 3 trials have entered long term extension
Over 1,000 patients now on Epidiolex treatment
NDA submission to include safey data from over 1,500 patients and over 400 patients with 1 year or more continuous exposure
Withdrawal rate in long term studies approx 20%
Commercial:
US commercial team build underway and pre-launch preparations advancing well
EU commercial team now being established
Additional indications:
Phase 3 trial in TSC ongoing
Two part Phase 3 trial in IS commenced in December 2016
Intellectual Property:
Patent portfolio being prosecuted with claims directed to the use of CBD in the treatment of epilepsy seizure subtypes and epilepsy syndromes
Advanced clinical programs in multiple cannabinoid pipeline product candidates:
CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected mid-2017
CBDV pre-clinical research ongoing within field of autism spectrum disorders. Phase 2 trials expected to commence in Q3 2017
Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome
Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
Phase 1 trial commenced in December 2016
Orphan Drug and Fast Track Designations granted from FDA and EMA
THC:CBD for the treatment of Recurrent Glioblastoma Multiforme (GBM)
Phase 1b/2a study completed – data expected Q1 2017
Orphan Drug Designation from FDA
Sativex® Phase 2 study in children with spasticity due to cerebral palsy completed – data expected Q1 2017
FINANCIAL HIGHLIGHTS
Revenue for the twelve months ended 30 September 2016 of £10.3 million ($13.3 million) compared to £28.5 million for the twelve months ended 30 September 2015.
Loss for the twelve months ended 30 September 2016 of £63.7 million ($82.2 million) compared to £44.6 million for the twelve months ended 30 September 2015.
Cash and cash equivalents at 30 September 2016 of £374.4 million ($483.4 million) compared to £234.9 million as at 30 September 2015.
Conference Call and Webcast Information
GW Pharmaceuticals will host a conference call and webcast to discuss the fourth quarter and year-end 2016 financial results today at 8:00 a.m.. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010, (international):1-919-882-2331. For both dial-in numbers please use conference ID # 13650870.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Forward-looking statements
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the relevance of GW products commercially available and in development, the clinical benefits of Sativex® and Epidiolex® and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations
401 500 6570
Sam Brown (U.S. Media Enquiries)
Amanda Foley
+610 725 0725 / 610 585 9400
Solely for the convenience of the reader, unless otherwise indicated, all pound sterling amounts stated in the Condensed Consolidated Balance Sheet as at 30 September 2016, the Condensed Consolidated Income Statement, Condensed Consolidated Statement of Comprehensive Income, Condensed Consolidated Statement of Changes in Equity and the Condensed Consolidated Cash Flow Statement for the three months and for the year ended 30 September 2016 have been translated into U.S. dollars at the rate on 30 September 2016 of $1.29128 to £1.00. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date.
GW Pharmaceuticals plc Condensed consolidated income statement Three months ended 30 September 2016
Three months ended
Three months ended
Three months ended
30 September
30 September
30 September
2016
2016
2015
$000’s
£000’s
£000’s
Revenue
2,156
1,670
5,595
Cost of sales
(1,006
)
(779
)
(683
)
Research and development expenditure
(31,401
)
(24,318
)
(25,457
)
Sales, general and administrative expenses
(9,645
)
(7,469
)
(4,988
)
Net foreign exchange gain
8,099
6,272
6,874
Operating loss
(31,797
)
(24,624
)
(18,659
)
Interest and other income
408
316
83
Interest expense
(155
)
(120
)
(15
)
Loss before tax
(31,544
)
(24,428
)
(18,591
)
Tax benefit
9,710
7,520
6,358
Loss for the period
(21,834
)
(16,908
)
(12,233
)
Loss per share – basic and diluted
(7.4c)
(5.7p)
(4.7p)
All activities relate to continuing operations.
Condensed consolidated statement of comprehensive loss For the three months ended 30 September 2016
Three months ended 30 September 2016 £000’s
Three months ended 30 September 2015 £000’s
Loss for the period
(16,908
)
(12,233
)
Items that may be reclassified subsequently to profit or loss
Exchange differences on translation of foreign operations
183
(51
)
Other comprehensive gain/(loss) for the period
183
(51
)
Total comprehensive loss for the period
(16,725
)
(12,284
)
GW Pharmaceuticals plc Condensed consolidated income statement Year ended 30 September 2016
Year ended
Year ended
Year ended
30 September
30 September
30 September
2016
2016
2015
$000’s
£000’s
£000’s
Revenue
13,320
10,315
28,540
Cost of sales
(3,511
)
(2,719
)
(2,618
)
Research and development expenditure
(128,889
)
(99,815
)
(76,785
)
Sales, general and administrative expenses
(25,747
)
(19,939
)
(12,569
)
Net foreign exchange gain
32,993
25,551
6,202
Operating loss
(111,834
)
(86,607
)
(57,230
)
Other income
785
608
244
Interest expense
(223
)
(173
)
(75
)
Loss before tax
(111,272
)
(86,172
)
(57,061
)
Tax benefit
29,073
22,515
12,498
Loss for the year
(82,199
)
(63,657
)
(44,563
)
Loss per share – basic and diluted
(30.4c)
(23.5p)
(18.1p)
All activities relate to continuing operations.
Condensed consolidated statement of comprehensive loss For the year ended 30 September 2016
Year ended 30 September 2016 £000’s
Year ended 30 September 2015 £000’s
Loss for the year
(63,657
)
(44,563
)
Items that may be reclassified subsequently to profit or loss
Exchange differences on translation of foreign operations
349
(71
)
Other comprehensive gain/(loss) for the year
349
(71
)
Total comprehensive loss for the year
(63,308
)
(44,634
)
GW Pharmaceuticals plc Condensed consolidated statement of changes in equity Year ended 30 September 2016
Called-up
Share
share
premium
Other
Accumulated
Total
capital
account
reserves
deficit
equity
£000’s
£000’s
£000’s
£000’s
£000’s
Balance at 1 October 2014
237
220,551
19,260
(81,464
)
158,584
Issue of share capital
22
127,812
–
–
127,834
Expense of new equity issue
–
(271
)
–
–
(271
)
Exercise of share options
2
1,183
–
–
1,185
Share-based payment transactions
–
–
–
2,488
2,488
Loss for the year
–
–
–
(44,563
)
(44,563
)
Deferred tax attributable to unrealized share option gains
–
–
–
84
84
Other comprehensive expense
–
–
(71
)
–
(71
)
Balance at 30 September 2015
261
349,275
19,189
(123,455
)
245,270
Balance at 1 October 2015
261
349,275
19,189
(123,455
)
245,270
Issue of share capital
39
206,512
–
–
206,551
Expense of new equity issue
–
(472
)
–
–
(472
)
Underwriters’ contribution towards expenses of new equity issue
–
472
–
–
472
Exercise of share options
2
690
–
–
692
Share-based payment transactions
–
–
–
8,152
8,152
Loss for the year
–
–
–
(63,657
)
(63,657
)
Deferred tax attributable to unrealized share option gains
–
–
–
1,133
1,133
Other comprehensive expense
–
–
349
–
349
Balance at 30 September 2016
302
556,477
19,538
(177,827
)
398,490
GW Pharmaceuticals plc Condensed consolidated balance sheet As at 30 September 2016
As at 30 September
As at 30 September
As at 30 September
2016
2016
2015
Non-current assets
$000’s
£000’s
£000’s
Intangible assets - goodwill
6,728
5,210
5,210
Other intangible assets
812
629
245
Property, plant and equipment
50,291
38,947
28,733
Deferred tax asset
5,001
3,873
418
62,832
48,659
34,606
Current assets
Inventories
5,485
4,248
4,756
Taxation recoverable
27,533
21,322
12,641
Trade receivables and other assets
5,883
4,556
2,873
Cash and cash equivalents
483,445
374,392
234,872
522,346
404,518
255,142
Total assets
585,178
453,177
289,748
Current liabilities
Trade and other payables
(40,249
)
(31,170
)
(24,022
)
Current tax liabilities
(1,140
)
(883
)
(366
)
Obligations under finance leases
(272
)
(211
)
(111
)
Deferred revenue
(3,468
)
(2,686
)
(3,269
)
(45,129
)
(34,950
)
(27,768
)
Non-current liabilities
Trade and other payables
(12,168
)
(9,423
)
(8,445
)
Obligations under finance leases
(6,403
)
(4,959
)
(1,540
)
Deferred revenue
(6,915
)
(5,355
)
(6,725
)
Total liabilities
(70,615
)
(54,687
)
(44,478
)
Net assets
514,563
398,490
245,270
Equity
Share capital
390
302
261
Share premium account
718,568
556,477
349,275
Other reserves
25,229
19,538
19,189
Accumulated deficit
(229,624
)
(177,827
)
(123,455
)
Total equity
514,563
398,490
245,270
GW Pharmaceuticals plc Condensed consolidated cash flow statement As at 30 September 2016
Year ended
Year ended
Year ended
30 September 2016
30 September 2016
30 September 2015
$000’s
£000’s
£000’s
Loss for the year
(82,199
)
(63,657
)
(44,563
)
Adjustments for:
Other income
(785
)
(608
)
(244
)
Interest expense
223
173
75
Tax benefit
(29,073
)
(22,515
)
(12,498
)
Depreciation of property, plant and equipment
4,654
3,605
2,250
Impairment of property, plant and equipment
–
–
606
Amortization of intangible assets
80
62
52
Net foreign exchange gains
(32,993
)
(25,551
)
(6,282
)
Increase in provision for inventories
93
72
33
Decrease in deferred signature fees
(1,511
)
(1,170
)
(1,250
)
Share-based payment charge
10,527
8,152
2,478
Loss on disposal of property, plant and equipment
1
1
1
(130,983
)
(101,436
)
(59,342
)
Decrease/(increase) in inventories
563
436
(12
)
Increase in trade receivables and other assets
(972
)
(753
)
(1,010
)
Increase in trade and other payables and deferred revenue
6,148
4,761
8,478
Cash used in operations
(125,244
)
(96,992
)
(51,886
)
Income taxes paid
(1,140
)
(883
)
–
Research and development tax credits received
17,150
13,281
5,415
Net cash outflow from operating activities
(109,234
)
(84,594
)
(46,471
)
Investing activities
Interest received
560
434
236
Purchases of property, plant and equipment
(11,206
)
(8,678
)
(17,915
)
Purchase of intangible assets
(661
)
(512
)
(114
)
Proceeds from sales of property, plant and equipment
–
–
2
Net cash outflow from investing activities
(11,307
)
(8,756
)
(17,791
)
Financing activities
Proceeds on exercise of share options
697
540
1,185
Proceeds of new equity issue
266,714
206,550
127,834
Expenses of new equity issue
(412
)
(319
)
(271
)
Underwriters’ contribution towards expenses of new equity issue
609
472
–
Interest paid
(89
)
(69
)
(74
)
Repayments of advance funding
(310
)
(240
)
–
Repayments of obligations under finance leases
(164
)
(127
)
(255
)
Net cash inflow from financing activities
267,045
206,807
128,419
Effect of foreign exchange rate changes on cash and cash equivalents
33,655
26,063
6,224
Net increase in cash and cash equivalents
180,159
139,520
70,381
Cash and cash equivalents at beginning of the year